We are live on ! Find out more
CCM

Copernicus Capital Management Portfolio holdings

AUM $8.26M
1-Year Est. Return 37.91%
This Fund
S&P 500
This Quarter Est. Return
+39.9%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$91.2M
AUM Growth
+$8.59M
Cap. Flow
-$4.3M
Cap. Flow %
-4.71%
Top 10 Hldgs %
79.32%
Holding
27
New
13
Increased
1
Reduced
4
Closed
9

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$9.69M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$9.02M
3
AMGN icon
Amgen
AMGN
+$7.53M
4
IQV icon
IQVIA
IQV
+$5.42M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$4.75M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$9.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.17M
3
CVS icon
CVS Health
CVS
+$7.71M
4
MCK icon
McKesson
MCK
+$6.9M
5
BIIB icon
Biogen
BIIB
+$5.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$454B
$10.8M 11.84%
+110,000
New +$9.69M
BMY icon
2
Bristol-Myers Squibb
BMY
$126B
$10.1M 11.05%
171,493
-5,504
-3% -$329K
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$9.54M 10.46%
+85,000
New +$9.02M
AMGN icon
4
Amgen
AMGN
$201B
$7.78M 8.53%
+33,000
New +$7.53M
VRTX icon
5
Vertex Pharmaceuticals
VRTX
$120B
$6.47M 7.1%
22,305
-30,148
-57% -$8.17M
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.4B
$6.15M 6.74%
49,889
-53,290
-52% -$5.3M
IQV icon
7
IQVIA
IQV
$34.6B
$5.67M 6.22%
+40,000
New +$5.42M
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.51M 6.04%
+57,000
New +$4.75M
FATE icon
9
Fate Therapeutics
FATE
$294M
$5.33M 5.85%
155,505
-5,454
-3% -$163K
ARNA
10
DELISTED
Arena Pharmaceuticals Inc
ARNA
$5.01M 5.5%
79,672
+34,672
+77% +$1.91M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.7M 5.16%
+84,626
New +$3.62M
RCUS icon
12
Arcus Biosciences
RCUS
$3.74B
$3.08M 3.37%
+124,404
New +$3.36M
MNTA
13
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.93M 3.21%
+88,000
New +$2.8M
GWPH
14
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$2.7M 2.96%
+22,000
New +$2.5M
EIGR
15
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.92M 2.1%
+6,667
New +$1.97M
TBIO
16
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$1.61M 1.77%
+90,000
New +$1.36M
CBAY
17
DELISTED
Cymabay Therapeutics
CBAY
$1M 1.1%
+287,000
New +$828K
OSUR icon
18
OraSure Technologies
OSUR
$277M
$917K 1.01%
+78,875
New +$1.02M
BIIB icon
19
Biogen
BIIB
$29.6B
– –
-18,000
Closed -$5.7M
CI icon
20
Cigna
CI
$75.7B
– –
-54,748
Closed -$9.7M
CNC icon
21
Centene
CNC
$31.5B
– –
-47,000
Closed -$2.79M
CVS icon
22
CVS Health
CVS
$136B
– –
-130,000
Closed -$7.71M
MCK icon
23
McKesson
MCK
$96.5B
– –
-51,000
Closed -$6.9M
TMO icon
24
Thermo Fisher Scientific
TMO
$213B
– –
-18,896
Closed -$5.36M
TNDM icon
25
Tandem Diabetes Care
TNDM
$1.16B
– –
-42,685
Closed -$2.75M
1
2

Similar funds

AAM
Areion Asset Management Hong Kong $7.82M AUM 16% 1-Year Est. Return
IR
Invictus RG Hamilton, Bermuda $8.9M AUM 56.32% 1-Year Est. Return
YEPV
Yorktown Energy Partners VI New York $6.21M AUM 74.4% 1-Year Est. Return
LC
Lunia Capital Dallas, Texas $4.49M AUM 42.82% 1-Year Est. Return
MA
MANA Advisors New York $3.06M AUM 7.13% 1-Year Est. Return
IFC
Intact Financial Corporation Toronto, Ontario, Canada $14M AUM
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Copernicus Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Copernicus Capital Management held 27 positions worth $91.2M, up 10% from $82.6M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Copernicus Capital Management withdrew a net $4.3M in Q2 2020, closing 9 positions and reducing 4 holdings. Its most notable exit was Cigna, an estimated $9.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Copernicus Capital Management opened a new position in AbbVie worth $10.8M.

  • Copernicus Capital Management's largest Q2 2020 buy was AbbVie: 110,000 shares worth $10.8M.
  • Copernicus Capital Management added most to Arena Pharmaceuticals Inc in Q2 2020, an estimated $1.91M increase.
  • Copernicus Capital Management's biggest Q2 2020 reduction was Vertex Pharmaceuticals, cutting an estimated $8.17M.
  • Copernicus Capital Management fully exited Cigna in Q2 2020, selling an estimated $9.7M.
  • Copernicus Capital Management's ten largest holdings make up 79% of its $91.2M portfolio in Q2 2020.
  • Copernicus Capital Management opened 13 new positions and closed 9 in Q2 2020.
  • Copernicus Capital Management's portfolio value rose 10% quarter-over-quarter to $91.2M.

Based on Copernicus Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.